| 1.1 | “Affiliate”      shall mean any person or entity which, directly or indirectly, controls,      is controlled by, or is under common control with, a party or its      assignee.  Control shall be determined based upon either their      legal right to control or de facto control of the  entity. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.2 | “Agreement”      shall have the meaning set forth in the Preamble and shall include any      exhibits and attachments hereto. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------|

| 1.3 | “NDA”      shall mean any new drug application required to manufacture, market and      sell finished dosage forms of the Products in the Territory (as defined      herein) filed by Mikah with the FDA pursuant to the applicable part of 21      CFR, and any supplements and amendments thereto which may be filed by      Mikah from time to time. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   | EXECUTION      COPY |
|--------|--------|---------------------|

----

| 1.4 | “ANDA”  means      Abbreviated New Drug Application number 75-274 (Naltrexone Hydrochloride      Tablets USP, 50mg) and all amendments thereto, that have to date been      filed with the FDA seeking authorization and approval to manufacture,      package, ship and sell, as more fully defined in 21 C.F.R Part 314 of the      FD&C Act. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.5 | “API”      shall mean the active pharmaceuticalingredient. |
|-----|------------------------------------------------------------------------|

| 1.6 | “Applicable      Laws” shall mean all laws, ordinances, codes, rules and regulations      applicable to the manufacturing of the Product or any aspect thereof and      the obligations of Elite or Mikah, as the context requires under this      Agreement, including, without limitation: (i) all applicable federal,      state and local laws and regulations of the Territory (including      Environmental Laws); (ii) the U.S. Federal Food, Drug and Cosmetic Act,      and (iii) the Regulations promulgated under the FD&C Act including      without limitation those regarding the Good Manufacturing Practices      (“cGMP”), each as amended from time to time and (iv) all laws ordinances,      codes, rules and regulations of the Manufacturer as they apply to the      Product. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.7 | “Competitive      Product” shall mean a similar dosage form containing {***}or equivalent,      that is {***}tablet. |
|-----|----------------------------------------------------------------------------------------------------------------------------------|

| 1.8 | “Data”      shall refer to all data, materials, plans, reports, test results and other      information developed solely by Elite in connection with the Elite      Development Activities. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.9 | “Elite      Development Activities” has the meaning set forth in Section      2.1. |
|-----|------------------------------------------------------------------------------------------------|

| 1.10 | “Facility”      shall mean Elite’s finished product manufacturing facility located at 165      Ludlow Avenue, Northvale, New Jersey or any other Elite controlled      facility approved by Mikah. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.11 | “FDA”      shall mean the United States Food and Drug  Administration. |
|------|------------------------------------------------------------------------------------|

| 1.12 | “FD&C      Act” shall mean the United States Federal Food, Drug and Cosmetics Act,      (21 U.S.C. 301, et seq.), as amended from time to time, and any regulation      promulgated hereunder, including, without limitation, all current good      manufacturing practices and current good laboratory practices as defined      therein, in each case, as amended from time to  time. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.13 | “Finished      Goods” means the Product in its final commercial  package. |
|------|---------------------------------------------------------------------------------------|

| 1.14 | “Force      Majeure” shall mean the occurrence of an event which materially interferes      with the ability of a Party to perform its obligations or duties hereunder      which is not within the reasonable control of the Party affected, not due      to malfeasance, and which could not with the exercise of due diligence      have been avoided, including, but not limited to, fire, accident, work      stoppage, sabotage, strike, riot, civil commotion, terrorism, act of God      or change in law. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2 | EXECUTION      COPY |
|--------|---|---------------------|

----

| 1.15 | “GAAP”      shall refer to United States generally accepted accounting principles,      consistently applied. |
|------|---------------------------------------------------------------------------------------------------------------------------|

| 1.16 | “Good      Manufacturing Practices” or “cGMP” shall mean the current good      manufacturing practices for manufacturing finished products and active      pharmaceutical ingredients as set forth in the FD&C Act, their      attendant rules and regulations, and any other current good manufacturing      practices which are applicable to theFacility |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.17 | “Know-How”      means proprietary know-how, trademarks, inventions, data, technology and      information relating to Product, which either party hereto has the lawful      right to disclose to the other party. “Know-How” shall include, without      limitation, processes and analytical methodology used in development,      testing, analysis and manufacture and medical, clinical, toxicological      testing as well as other scientific data relating to    Product. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.18 | “Milestone      Timetable” shall mean the mutually agreed dates upon which Elite is      obligated to complete the specific components of the Elite Development      Activities with respect to {***}, as evidenced in Exhibits A and B      hereto. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.19 | “Naltrexone      Product” means the following properties, assets and rights of whatever      kind and nature, tangible or intangible, of Mikah, existing on the      Effective Date that relate solely and exclusively to the ANDA and any      testing, data, studies, and formulations created in connection therewith,      including, without limitation: (i) the ANDA, (ii) any correspondence with      the FDA in Mikah’s possession with respect to the ANDA, (iii) the right of      reference to the Drug Master Files, as set forth in the ANDA; (iv) the      ANDA Technology and Scientific Materials; and (v) a fully-paid, perpetual,      royalty-free, exclusive license to use any Naltrexone Product technology      which is associated with or incorporated in the Naltrexone Product, and to      include the same in any other product of Mikah, but only for Elite’s use      in connection with the manufacture in the Territory of the Naltrexone      Product. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.20 | “Net      Sales” means all proceeds received by Mikah and/or its Affiliates and/or      from Mikah’s successors and/or from unaffiliated third parties from sales,      of {***}in the Territories, less returns, samples, allowances, discounts      and applicable taxes, as reflected on actual customer invoices, as may be      applicable. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.21 | “Product”      means {***}Tablets, strengths of {***}mg, {***} mg, and {***}      mg. |
|------|---------------------------------------------------------------------------------------------------|

| 1.22 | “Regulatory      Approvals” shall mean the approvals required under the FD&C Act to      sell and market the Product in theTerritory. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.23 | “Regulatory      Requirements” shall mean any requirements under or pursuant to the      FD&C Act or other ApplicableLaws. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3 | EXECUTION      COPY |
|--------|---|---------------------|

----

| 1.24 | “Regulatory      Standards” shall mean (a) the Facility license requirements, including      good laboratory practices, and the Good Manufacturing Practice regulations      applicable to the Facility or Elite's research and development,      production, packaging, storage or handling of Product at the Facility and      (b) any standards of any governmental authority, including good laboratory      practices, within the Territory, that apply to the Facility, Elite’s      research and development facilities or Elite’s production, packaging,      storage or handling of the Product. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.25 | “Specifications”      with respect to the Product shall mean the development, manufacturing,      quality control, packaging, labeling, shipping and storage specifications      in the applicable USP/NF monograph, the DMF or other Regulatory Filing, in      the form of specifications set forth as part of this Agreement, including      without limitation, those set forth on Exhibit C hereto, and such      specifications as may from time to time be established by applicable      Regulatory Authorities and as mutually agreed upon by the      Parties. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.26 | “Territory”      means the United States of America, its territories, possessions,      commonwealths. |
|------|--------------------------------------------------------------------------------------------------------------------|

| 2.1 | Product      Development and Development Activities for Elite.  Except as      provided for in Section 2.2 of this Agreement, Elite, at its own cost and      expense, shall undertake and perform all reasonably necessary development      work to create a robust formulation, analytical development and perform      all other developmental actions necessary or required to facilitate the      preparation of a Regulatory Filing for {***}, as more fully set forth as      Elite responsibilities on Exhibit A (the “Elite Development      Activities”)  For purposes of further clarification, Elite      Development Activities conducted by Elite shall include, without      limitation, each of the following in accordance with applicable      regulations and establishedSpecifications: |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | a. | Tested      and validated API, raw materials, packaging and components that are      selected from an FDA approvedvendor. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------|

|   | b. | Formulation      development resulting in a formulation that will pass the USP and all      other specifications required by FDA for {***}that leads to an approved      NDA. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | c. | Analytically      developed methods (such as content dissolution, related substances,      etc.); |
|--------|----|---------------------------------------------------------------------------------------------------|

|   | d. | Manufacturing      clinical supplies. exhibit batches and validation batches (three      validation batches of eachstrength); |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------|

|   | e. | Conducting      stability studies in accordance with cGMP, applicable laws,including room      temperature and accelerated stability for each  lot; |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4 | EXECUTION      COPY |
|--------|---|---------------------|

----

|   | f. | Writing      the CMC section and compiling, the documents, data and dossier necessary      for the filing of an NDA for the {***}that is adequate for Mikah to obtain      final NDA approval. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.2 | Product      Development and Sales Activities for Mikah.  Mikah will be      responsible for biostudies, regulatory filings and sales and distribution      of the Product. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | a. | Mikah      or its designees shall prepare all applications necessary to obtain any      Product registration and permits required to file the Product in the      Territories.  The NDA shall be owned by Mikah.  Elite,      however, shall write the CMC section and prepare all completed data and      information deemed necessary for the filing of a valid  NDA. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | b. | Mikah      will be responsible for any biostudies required for the      Product. |
|--------|----|----------------------------------------------------------------------------------|

| 2.3 | Ownership      of Regulatory Filings.  Mikah shall own and maintain the NDA,      Regulatory Approvals and any other jurisdictionally required Regulatory      Filings for the Product. Elite will offer any assistance as reasonably      requested with maintenance of the Regulatory Filings, as Mikah or a      Regulatory Authority may require. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.4 | Exclusive      Rights.  Elite does not have any right, title or interest in or      to the Data or any other information generated in connection with the      Elite Development Activities other than as covered in Article 6 and shall      not use the Data for any purpose other than as expressly provided      herein.  Elite agrees that to violate this provision would cause      Mikah significant and irreparable harm and accordingly, Mikah may seek an      injunction against Elite in thisevent. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1 | Manufacturing      Agreement.  Elite and Mikah agree that, upon approval of the NDA      for {***}, Elite will manufacture the Product and the Parties will      negotiate in good faith a manufacturing and supply agreement for the      Product. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5 | EXECUTION      COPY |
|--------|---|---------------------|

----

| 4.1 | Mikah,      its Affiliates and/or its successors shall pay Elite on a quarterly basis      a royalty payment as set forth in Exhibit B, item 4 (the “Royalty”), and      provide a quarterly report of all Productsales. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.2 | The      Royalty shall be due and payable for the duration of the period beginning      on the date of approval of the Product by the FDA and ending on the date      of introduction into the market of a generic of {***} (such period being      the “Royalty Period”). |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.3 | Payment      of the Royalty is contingent upon the Product being manufactured by Elite      in a US-FDA approved facility, except as provided for in Article 11 of      this Agreement. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.4 | All      payments and quarterly sales reports shall be made within forty five (45)      days after the end of each quarter starting with the end of the calendar      quarter immediately following the commercial launch of the      Product. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.5 | Audit      rights for accounts. Upon ten days written notice, Elite shall have the      right to designate a representative to inspect Mikah’s books of account,      records, documents and instruments related to the sales of the Product of      Mikah and any Affiliate and to make copies thereof, at any time during      Mikah’s regular business hours during the term of this Agreement and for a      period of) two (2) years immediately after termination of this Agreement      to ascertain the accuracy of such records in respect to calculation of      royalty amounts. The expense of such audit shall be Elite’s unless the      audit shall demonstrate a discrepancy greater than five percent (5%)      between royalties reported and paid and those which were actually      incurred, in which event the expenses of such audit shall be borne by      Mikah. In the event there is a dispute between Elite and Mikah regarding      any discrepancy discovered by such audit, Mikah and Elite shall together      designate a qualified third party certified public accountant to perform a      second audit, the results of which shall be binding. In the event the      second audit reveals that the discrepancy was less than five percent (5%),      then Elite shall pay the costs of the second audit. In the event that the      second audit reveals that the discrepancy was more than five percent (5%),      then Mikah shall pay the cost of the second  audit. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.1 | Payments      for Development.  In consideration of Elite’s performance with      the terms and conditions of this agreement, Mikah shall pay Elite for the      development work according to the terms outlined in exhibit B, items 1,2      and 3, of this agreement. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.2 | Grant      of License.  Subject to the terms set forth herein, and in      consideration for the payments set forth, Elite hereby grants to Mikah a      royalty bearing license to market the Product within the Territory. The      royalty amount is set forth in Exhibit B, item 4, and is contingent upon      FDA approval of the Product and Article 4 of this    Agreement. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6 | EXECUTION      COPY |
|--------|---|---------------------|

----

| 6.1 | Representations      and warranties: |
|-----|--------------------------------------|

|   | (a) | Each      Party represents and warrants to the other that it is authorized to enter      into and to perform its obligations under this  Agreement. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Each      Party represents and warrants to the other that its obligations created      under this agreement do not conflict in any manner with any of its      pre-existing obligations. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | Each      Party represents and warrants to the other that it is the owner of any      Know-How to be used or relied upon by such Party in performing its      obligations under this Agreement. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | Mikah      represents and warrants that: |
|--------|-----|------------------------------------------|

|   | (i) | it      has not received any notice or claim that the use of its Know-How      infringes any patent or intellectual property rights of any third party in      the Territory; and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | to      its actual knowledge, without any independent investigation, the use of      its Know-How will not infringe any patent or intellectual property rights      of any third party in theTerritory. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (e) | Elite      represents and warrants that: |
|--------|-----|------------------------------------------|

|   | (i) | It      has not received any notice or claim that the use of its Know-How      infringes any patent, or intellectual property rights of any third party      in the Territory; and |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | to      its actual knowledge, without any independent investigation, the use of      its Know-How will not infringe any patent or intellectual property rights      of any third party in theTerritory. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 7 | EXECUTION      COPY |
|--------|---|---------------------|

----

| 7.1 | Each      Party shall be responsible, at its own expense, for filing and prosecuting      patent applications relating to its Know-How, as it deems appropriate, and      for paying maintenance fees on any patents issuing there from, for the      term of this Agreement, with respect to Know-How owned by      it.  With respect to any Product developed hereunder, the party      developing the formulation shall be responsible for filing and prosecuting      the patents.  Each Party shall promptly render all necessary      assistance reasonably requested by the other Party in applying for      and prosecuting patent applications relating to such Party’s Know-How      under this Agreement. Ownership of inventions shall be determined by US      Patent Law.   Notwithstanding the foregoing, to the extent      that a patent application includes claims applicable to a broader scope of      products than the Product, such Know-How and rights related thereto shall      be presumed to belong to Elite, provided that Mikah shall receive a fully      paid up license for such patent with respect to the Product during the      life of the patent. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2 | For      avoidance of doubt, Elite shall retain ownership of any Intellectual      Property, which it owned prior to the execution of this Agreement and      which has not been created or developed in connection with the provision      of the activities contemplated hereunder. In such event, Elite shall grant      Mikah a non-exclusive, royalty-free, sub-licensable, perpetual license to      use Elite Intellectual Property solely in connection with the activities      contemplated hereunder, and/or as is necessary or useful to the      commercialization of the Product, including but not limited to making,      having made, using, importing, exporting, and selling the      Product. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.1 | Indemnification      of Mikah. Elite shall indemnify and hold harmless Mikah and its officers,      directors and employees against and from any losses, damages, injuries,      liabilities, exposure, claims, demands, settlement, judgments, awards,      fines, penalties, taxes, fees (including attorneys’ fees), charges or      expenses that are suffered or incurred at any time by Mikah or such      persons, or to which Mikah or such persons may otherwise become subject at      any time, and that become payable or arise out of or by virtue of, or      relate to: |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | Any      breach by Elite or default by Elite in the performance of, or any failure      on the part of Elite to observe, perform or abide by, any restriction,      covenant, obligation, representation, warranty or other provision      contained in this Agreement or |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Any      injury or alleged injury to any person (including death) or to the      property of any person not a party hereto arising out of or alleging the      negligence or intentional act or omission of Elite or its employees or      agents. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2 | Indemnification      of Elite. Mikah shall indemnify and hold harmless Elite and its officers,      directors or employees against and from any losses, damages, injuries,      liabilities, exposure, claims, demands, settlement, judgments, awards,      fines, penalties, taxes, fees (including attorneys’ fees), charges or      expenses that are suffered or incurred at any time by Elite or such      persons, or to which Elite or such persons may otherwise become subject at      any time, and that become payable or arise out of or by virtue of, or      relate to: |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 8 | EXECUTION      COPY |
|--------|---|---------------------|

----

|   | (a) | Any      breach by Mikah or default by Mikah in the performance of, or any failure      on the part of Mikah to observe, perform or abide by, any restriction,      covenant, obligation, representation, warranty or other provision      contained in this Agreement or |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Any      injury or alleged injury to any person (including death) or to the      property of any person not a party hereto arising out of or alleging the      negligence or intentional act or omission of Mikah or its employees or      agents, or arising from the active ingredient of the    Product. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.3 | Notice      and Legal Defense. Promptly after receipt by a Party hereunder of any      claim or notice of the commencement of any action, administrative or legal      proceeding, or investigation as to which the indemnity provided for in      Section 7.1 and 7.2 hereof may apply, the Party seeking indemnification      shall notify the indemnifying Party in writing of such fact The      indemnifying Party shall assume the defense thereof; provided, however,      that if the defendants in any such action include both the Party seeking      indemnification and the indemnifying Party and the Party seeking      indemnification shall reasonably conclude that there may be legal defenses      available to it which are different from or additional to, or inconsistent      with, those available to the indemnifying Party, the Party seeking      indemnification shall have the right to select separate counsel to      participate in the defense of such action on behalf of such Party seeking      indemnification, at the indemnifying Party’s  expense. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.4 | LIMITATION      OF DAMAGES. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY      FOR LOST PROFITS (OTHER THAN AS ARE ORDINARILY ENCOMPASSED BY CONTRACT      DAMAGES), LOSS OF GOODWILL, OR ANY SPECIAL, INDIRECT, CONSEQUENTIAL OR      INCIDENTAL DAMAGES, HOWEVER CAUSED, ARISING UNDER ANY THEORY OF LIABILITY.      THIS LIMITATION SHALL APPLY EVEN IF A PARTY HAS BEEN ADVISED OF THE      POSSIBILITY OF SUCH DAMAGES, AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL      PURPOSE OF ANY LIMITED REMEDY. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.1 | Term.  This      Agreement shall be effective from the Effective Date and shall continue      for a ten (10) year term after the initial marketing of the Product, or      pursuant to Article 9 of this Agreement. For avoidance of doubt, the      Royalty shall be due and owing only during the “Royalty Period” if the      “Royalty Period” is less than ten years.  One year prior to the      Termination Date, the Parties shall meet to discuss the commercial options      regarding the supply and distribution of the Product subsequent to such      Termination Date. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 9 | EXECUTION      COPY |
|--------|---|---------------------|

----

| 9.2 | Termination.  Either      Party shall have the option to terminate this Agreement prior to the      Termination Date upon the occurrence of a "Termination      Event".  A "Termination Event" shall mean: (a) the voluntary or      involuntary filing of a petition for bankruptcy, insolvency or placing in      receivership of either Party; (b) a material breach of the terms of this      Agreement by one Party followed by written notice of such breach by the      non-breaching Party followed by the failure of the breaching Party to cure      such breach within sixty (60) days of the date upon which written notice      of breach was given as in Section 9.4; (c) adverse changes in the      Intellectual Property environment wherein either Party, in its reasonable      commercial judgment believes a third party patent may be infringed upon by      a Product; (d) upon six (6) months written notice to the other Party, if      in terminating Party’s reasonable judgment the Product ceases to be      commercially viable. Otherwise, if Mikah is to terminate for any reason      other than that which is set forth in Article 9.2, Mikah shall pay Royalty      to Elite for the Royalty Period.  If Elite is to terminate for      any reason other than that which is set forth in Article 9.2, the Royalty      shall not be due and owing to Elite for the period subsequent to such      termination. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.3 | Termination      Prior to Regulatory Approvals.   Promptly upon termination      of this Agreement as a result of Elite’s bankruptcy or breach of this      Agreement prior to obtaining Regulatory Approvals, Mikah shall be entitled      to a licensed copy of all of Elite’s Data or other materials reasonably      necessary to enable Mikah to complete the process of obtaining Regulatory      Approvals that have not yet been received, and in such case, the ownership      rights of Elite and Mikah with respect to the Product shall remain in      accordance with the provisions of this  Agreement. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.4 | Events of      Default. An event of default under this Agreement shall be deemed      to exist upon the occurrence of anyone or more of the following      events: |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | Failure      by either Party hereto to perform fully, or comply fully, with, any      material provision of this Agreement and such failure continues for a      period of sixty (60) days after receipt of written notice of such      nonperformance or noncompliance; |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Failure      of Mikah to pay any amount due to Elite, which failure continues for a      period of sixty (60) days after written notice of such non-payment unless,      and to the extent such non-payment is due to a good faith dispute      concerning the amount owed. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.5 | WARRANTY      LIMITATION. EXCEPT AS EXPRESSLY SET FORTH IN SECTION 6, THE PARTIES      MAKE NO WARRANTIES, EXPRESSED OR IMPLIED, CONCERNING TECHNOLOGY, GOODS,      SERVICES, RIGHTS OR THE MANUFACTURE AND SALE OF PRODUCTS, AND HEREBY      DISCLAIM: ANY OTHER WARRANTIES, INCLUDING WITHOUT LIMITATION ANY WARRANTY      OF MERCHANTABILITY, FITNESS FOR A PARTICULAR USE OR PURPOSE OR      NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE    FOREGOING. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 10 | EXECUTION      COPY |
|--------|----|---------------------|

----

| 10.1 | The      following dispute resolution process shall apply to all disputes that      arise under this Agreement (the “Dispute Resolution      Process”).  In the event of any dispute under this Agreement,      the disputing Party shall provide written notice of the dispute to the      other Parties detailing such dispute.  Within ten (10) business      days from the date of the written notice, the Parties will meet at a      mutually acceptable time and place or via phone or teleconference, and      thereafter as often as they reasonably deem necessary, to exchange      relevant information and to attempt to resolve the dispute.  If      they are unable to resolve the dispute within fifteen (15) business days      of their first meeting, the matter shall be referred to a senior board      level manager of each of theParties. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.2 | If      the senior board level managers of the Parties are unable to resolve the      matter within three (3) business days after notification then, any Party      to the dispute may initiate binding arbitration or pursue other legal      proceedings to the extent Section 10.4 of the Agreement is not      applicable. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.3 | Expenses.  Each      Party shall be responsible for its own legal fees, travel and related      expenses during the Parties’ attempt to resolve the    dispute. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.4 | Other      Rights.  Nothing in this Section 9 shall be deemed to waive the      right of any Party to apply to a court of competent jurisdiction for a      temporary restraining order, a preliminary injunction, or other equitable      relief to preserve the status quo or prevent irreparable    harm. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | ARTICLE      11 |
|--------|-----------------|

|   | MISCELLANEOUS |
|--------|---------------|

| 11.1 | Recitals.  The      recitals are hereby incorporated by reference and made part of this      Agreement. |
|------|-------------------------------------------------------------------------------------------------------------------|

| 11.2 | Survival.  Except      as expressly provided in this Agreement, expiration or termination of this      Agreement will not relieve the Parties of any obligation that accrued      prior to such expiration or termination. Upon expiration or early      termination of this Agreement, all rights and obligations of the Parties      shall cease, except as follows: |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | The      obligations of Article 4 of this Agreement, specifically the payment of      Royalties, shall survive termination of this Agreement up to and including      the date that is ten (10) years after the initial marketing of the      Product; or the last day of the Royalty Period, whichever is      earlier.  In the event of Elite being willing and able to      manufacture the Product in an Elite Facility and Mikah transferring such      manufacturing to a non-Elite facility, the Parties agree that the Royalty      shall continue to be due and payable to Elite regardless of the Product      not being manufactured in an Elite facility.  For avoidance of      doubt, Royalty will be paid as specified in Article 4.2 (the “Royalty      Period”). |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 11 | EXECUTION      COPY |
|--------|----|---------------------|

----

|   | (b) | The      obligations of confidentiality set forth in Section 11.5 of Article 11      shall survive; |
|--------|-----|-----------------------------------------------------------------------------------------------------|

|   | (c) | The      Parties obligations under Article 7 shall  survive; |
|--------|-----|--------------------------------------------------------------|

|   | (d) | Any      cause of action or claim of Mikah or Elite      accrued or to accrue because of any breach or default by the other Party      hereunder shall survive;and |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.3 | Entire      Agreement; Amendment.  This Agreement, with all of the Exhibits,      contain the entire understanding of the Parties with respect to the      subject matter hereof and supersede all previous verbal and written      agreements, representations and warranties.  This Agreement may      be released, waived or modified only by written agreement signed by the      Party against whom enforcement of any release, waiver, modification, or      other change is sought. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.4 | Standard      Forms.  In ordering and delivering the services or Product,      Mikah and Elite may employ their standard forms, but nothing in those      forms shall be construed to modify, amend or supplement the terms of this      Agreement and, in the case of any conflict herewith, the terms of this      Agreement shall govern and control. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.5 | Confidentiality.  Elite      and Mikah shall not use, except in connection with this Agreement, nor      disclose any information concerning the other Party's business or any      proprietary information of the other Party, including but not limited to,      technical or scientific data, unpublished findings, biological material,      know-how, specifications, processes, techniques, patent, patent litigation      strategies or tactics, trade secrets, algorithms, programs, designs,      drawings, or formulae; and any engineering, manufacturing, marketing,      financial, litigation, intellectual property or business plan,      confidential knowledge, data or other similar information, whether      received pursuant to this Agreement or otherwise ("Confidential      Information") without the prior written consent of such other      Party.  The obligation of non-disclosure referred to above shall      not apply to: |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | Information      which is known to the receiving Party or one of its Affiliates or      independently developed by the receiving Party or one of its Affiliates      prior to the time of disclosure, in each case, to the extent evidenced by      written records; |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | Information      disclosed to the receiving Party by a third party, which has a right to      make such disclosure; |
|--------|------|---------------------------------------------------------------------------------------------------------------------|

|   | (iii) | Information      which is or becomes patented, published or otherwise part of the public      domain as a result of acts by the disclosing Party or a third person      obtaining such information as a matter of right;  or |
|--------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 12  | EXECUTION      COPY |
|--------|----------|---------------------|

----

|   | (iv) | Information      which is required to be disclosed by order of the FDA or similar authority      in other countries or a court of competent jurisdiction; provided that the      Parties shall use their best efforts to obtain confidential treatment of      such information by the court oragency. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.6 | In      addition to the provisions set forth in this agreement, the Mutual      Confidentiality Agreement entered into by the Parties dated as of May      18 ,      2010 is hereby incorporated herein by reference in its      entirety. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.7 | Force      Majeure.  Failure of any Party to perform its obligations under      this Agreement as a result of Force Majeure shall not subject such Party      to any liability or place it in breach of any term or condition of this      Agreement to the other Party if such failure is caused by any cause beyond      the reasonable control of such non-performing Party. The Party prevented      from performing its obligations or duties because of Force Majeure shall      promptly notify the other Party hereto of the occurrence and particulars      of such Force Majeure and shall provide the other Party, from time to      time, with its best estimate of the duration of such Force Majeure and      with notice of the termination thereof.  The Party so affected      shall use its best efforts to avoid or remove such causes of      nonperformance. Upon termination of Force Majeure, the performance of any      suspended obligation or duty shall promptly recommence.  Neither      Party shall be liable to the other Party for any direct, indirect,      consequential, incidental, special, punitive or exemplary damages arising      out of or relating to the suspension or termination of any of its      obligations or duties under this Agreement by reason of the occurrence of      Force Majeure.  In the event that Force Majeure has occurred and      is continuing for a period of at least three (3) months, the other Party      shall have the right to terminate this Agreement upon thirty (30) days      notice. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.8 | Waiver.  The      failure of a Party to enforce any breach or provision of this Agreement      shall not constitute a continuing waiver of such breach or provision and      such Party may at any time thereafter act upon or enforce such breach or      provisions of this Agreement.  Any waiver of breach executed by      either Party shall affect only the specific breach and shall not operate      as a waiver of any subsequent or preceding  breach. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.9 | No      Assignment.  Elite may not delegate, subcontract, sublicense or      otherwise transfer to a third party its rights or obligations under this      Agreement, except to any Affiliate of Elite, without the consent of      Mikah,  Mikah may transfer its rights or obligations under this      Agreement to any Affiliate or to a successor of the portion of its      business that is the subject matter hereof.  Subject to the      foregoing, this Agreement shall inure to the benefit of and be binding      upon the Parties and their respective permitted successors and      assigns. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.10 | Severability.  If      any clause or provision of this Agreement is declared invalid or      unenforceable by a court of competent jurisdiction, such provision shall      be severed and the remaining provisions of the Agreement shall continue in      full force and effect.  The Parties shall use their best efforts      to agree upon a valid and enforceable provision as a substitute for the      severed provision, taking into account the intent of this      Agreement. |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 13 | EXECUTION      COPY |
|--------|----|---------------------|

----

| 11.11 | Notices.  Any      notice, request or other communication required to be given pursuant to      the provisions of this Agreement shall be in writing and shall be deemed      to be given when delivered in person or by courier (return receipt      requested) or five days after being deposited in the United States mail,      postage prepaid, certified, return receipt requested to the Parties      addressed as follows: |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | If      to Elite, to: |
|--------|-----------------------|

|   | Elite      Laboratories, Inc. |
|--------|-------------------------------|

|   | 165      Ludlow Avenue Northvale |
|--------|----------------------------------|

|   | New      Jersey 07647 |
|--------|-----------------------|

|   | Attn:      Chris Dick, President |
|--------|----------------------------------|

|   | Fax:      (201) 750-2755 |
|--------|--------------------------|

|   | If      to Mikah to: |
|--------|----------------------|

|   | Mikah      Pharma, LLC |
|--------|------------------------|

|   | 20      Kilmer Drive |
|--------|----------------------|

|   | Hillsborough,      New Jersey 08844 |
|--------|-------------------------------------|

|   | Attn:      Nasrat Hakim, President |
|--------|------------------------------------|

| 11.12 | Governing      Law.  This Agreement shall be governed by and construed in      accordance with the laws of New Jersey, United States of America, without      reference to conflicts of laws, rules or  principles. |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.13 | Independent      Parties. The relationship of the Parties under this Agreement is that of      independent contractors.  Neither Party shall be deemed to be      the agent of the other, nor shall the Parties be deemed to be partners or      joint venturers, and neither is authorized to take any action binding upon      the other.  Elite expressly acknowledges for itself, its      employees, agents and subcontractors, that none of them are employees of      Mikah and that none of them are entitled to participate in any benefit      plans of Mikah.  Elite further acknowledges that none of its      employees, agents or subcontractors are eligible to participate in any      benefit plans of Mikah, even if it is later determined that the status of      any of them was that of an employee during the period of this engagement      of Elite by Mikah. |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.14 | Costs.  Except      as otherwise provided in this agreement, each Party will pay its own costs      and expenses in connection with the negotiation, preparation, execution,      and performance of thisAgreement. |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.15 | Currency.  Wherever      a monetary currency is indicated throughout this Agreement, that currency      shall be United States Dollars, unless otherwise clearly      indicated. |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14 | EXECUTION      COPY |
|--------|----|---------------------|

----

| 11.16 | Days.  Wherever      reference is made to days, working days or any measurement of time in      days, calendar days shall be used regardless of weekends and      holidays. |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.17 | Sophisticated      Parties.  Each Party to this Agreement is a sophisticated      business party negotiating in good faith with the advice of legal      counsel.  Each Party is hereby advised to seek the advice of      legal counsel prior to executing thisAgreement. |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.18 | English      Language.  This Agreement has been negotiated and is written in      the English language, and while some of the Parties may not speak English      as their primary language, they have sought the use of translators, if      necessary, and understand the meaning and implications of this entire      Agreement. |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 15 | EXECUTION      COPY |
|--------|----|---------------------|

----

| MIKAH      PHARMA LLC                          |   | ELITE      PHARMACEUTICALS, INC.  |
|------------------------------------------------|--------|-----------------------------------|
|                                           |   |                              |   |   |
| By:                                            |   |                              | By: |   |
| Name:Nasrat      Hakim                         |   | Name:Chris      C. Dick           |
| Title:        President      and CEO |   | Title:        President |

|   | 16 | EXECUTION      COPY |
|--------|----|---------------------|

----

|   |   |                                                                                                                                                                                                           |   | Responsibility |   |   |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------------|--------|--------|
| #      |   | Activities                                                                                                                                                                                                     |   | Elite          |   | Mikah  |   | Estimated Timing |
| 1      |   | Formulation Development-  Preliminary      batches-  API      and Raw Material characterization-  Comparator      product characterization-  In      vitro dissolution |   | X              |   |   |   | 6      months from signing of agreement |
| 2      |   | Analytics-  Product      specifications-  Methods      development-  Validation      package                                                                                     |   | X              |   |   |   |
| 3      |   | Manufacturing of Pivotal Batch-  Three      batches each strength (150,000 tablets)-  Packaging      in HDPE bottles                                                                       |   | X              |   |   |   | Immediately      after completion of Step 2 |
| 4      |   | Shelf Stability Studies-      Standard protocol for NDA- 3      batches X 3 strengths                                                                                                                          |   | X              |   |   |   |   |
| 5      |   | Biostudies                                                                                                                                                                                                     |   |           |   | X      |   | At      timing of Mikah |
| 6      |   | Validation                                                                                                                                                                                                     |   | X              |   |   |   |   |
| 7      |   | NDA:  Compile and      submit                                                                                                                                                                        |   |           |   | X      |   |   |

| Exhibit      A |   | CONFIDENTIAL |
|----------------|--------|--------------|

----

|   | 1. | For      the full development of {***}as per this agreement and its exhibits, Elite      shall receive all rights, title and interest held by Mikah in the      Naltrexone Product. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | a. | The      Parties agree to prepare and execute a separate asset purchase agreement      for the transfer of such rights, title and interest held by Mikah in the      Naltrexone Product within thirty days from the Effective    Date. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | The      Parties agree that the value of the Naltrexone Product, estimated at      $200,000, constitutes full and equitable consideration for the development      services being performed by Elite under this      Agreement.  Furthermore, the transfer of the Naltrexone Product      represents payment of consideration in lieu of cash, with such payment      being made by Mikah in advance of the performance of Elite Development      Activities. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3. | The      Parties agree, that in the event of Elite not completing any of those      Elite Development Activities listed as being the responsibility of Elite      as per Exhibit A of this Agreement, Elite shall pay to Mikah amounts, as      follows, with such amounts representing the value of consideration paid by      Mikah by transfer of the Naltrexone Product, less the value of Elite      Development Activities that werecompleted: |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | a. | If      Elite does not complete item #6 of Exhibit A (Validation), Elite shall pay      $25,000 to Mikah. |
|--------|----|-----------------------------------------------------------------------------------------------------------|

|   | b. | If      Elite does not complete item #’s 3 and 4 of Exhibit A (Manufacturing of      Pivotal Batch and Shelf Stability Studies, respectively), Elite shall pay      $100,000 to Mikah |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | c. | If      Elite does not complete item #’s 1 & 2 of Exhibit A (Formulation      Development and Analytics, respectively), Elite shall pay $75,000 to      Mikah. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4. | Royalties      of amounts equal to {***}% of Net Sales of {***}shall be paid to Elite in      accordance with the terms of this Agreement, including, without      limitation, Article 4 and Article11. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Exhibit      B |   | CONFIDENTIAL |
|----------------|--------|--------------|

----

| Exhibit      C |   | EXECUTION      COPY |
|----------------|--------|---------------------|

----